Caprock Group LLC Invests $7.23 Million in Gilead Sciences, Inc. $GILD

Caprock Group LLC bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 64,036 shares of the biopharmaceutical company’s stock, valued at approximately $7,234,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Rothschild Investment LLC boosted its stake in Gilead Sciences by 1.9% during the second quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after buying an additional 84 shares during the period. Hemington Wealth Management lifted its holdings in shares of Gilead Sciences by 9.3% in the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 85 shares during the last quarter. Ignite Planners LLC boosted its stake in shares of Gilead Sciences by 1.1% during the 3rd quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock worth $880,000 after purchasing an additional 86 shares during the period. Archer Investment Corp boosted its stake in shares of Gilead Sciences by 1.2% during the 2nd quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in Gilead Sciences by 0.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 34,711 shares of the biopharmaceutical company’s stock valued at $3,912,000 after purchasing an additional 87 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several analyst reports. Needham & Company LLC raised their price objective on shares of Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wolfe Research increased their price target on Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a report on Wednesday, January 28th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday, January 22nd. Truist Financial upped their price objective on Gilead Sciences from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, January 27th. Finally, UBS Group increased their target price on Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $136.73.

Gilead Sciences Trading Down 2.9%

Shares of NASDAQ GILD opened at $147.23 on Wednesday. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $153.13. The firm has a market cap of $182.67 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36. The business has a fifty day simple moving average of $128.39 and a two-hundred day simple moving average of $121.53. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to the consensus estimate of $7.68 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend is Friday, March 13th. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. Gilead Sciences’s payout ratio is 48.99%.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the transaction, the chief executive officer owned 613,912 shares in the company, valued at approximately $92,086,800. This represents a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is owned by corporate insiders.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat estimates: Gilead reported $1.86 EPS vs. a $1.83 consensus and revenue rose ~4.7% YoY, helping demonstrate underlying portfolio resilience. Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates
• Positive Sentiment: Dividend bump: Board raised the quarterly dividend by 3.8% to $0.82, supporting the stock’s income profile for yield‑focused investors. Gilead Sciences Announces 3.8% Dividend Increase
• Positive Sentiment: Pipeline and product momentum: Management cited growth in liver‑disease and HIV franchises and potential launches (including additional HIV options and two cancer therapy filings/approvals) and analysts remain upbeat on launches like Yeztugo. These could underpin medium‑term growth. WSJ: Gilead Profit Rises on Liver Disease, HIV Products Seeking Alpha: Q4 Preview
• Neutral Sentiment: Official earnings release and slide deck available for review — useful for digging into product-level trends and guidance assumptions. MarketWatch: Q4 and Full-Year Results
• Neutral Sentiment: Reported short‑interest data in filings is effectively meaningless/garbled for the period cited (shows 0 shares), so it provides no clear near‑term pressure signal.
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–$8.85 sits at the low end of Street forecasts and revenue guidance ($29.6–$30.0B) came in below consensus — the primary driver of the stock’s pullback as investors re‑price growth expectations. Benzinga: Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
• Negative Sentiment: Analyst/headline pushback: Several outlets flagged that the light outlook could weigh on the stock despite a clean beat, amplifying downward pressure in the session. Investor’s Business Daily: Light Outlook May Hurt Stock Reuters: Beat but Light Forecast
• Negative Sentiment: Insider selling: CEO disclosed a roughly $17.3M stock sale recently, which some investors view negatively even if driven by personal liquidity. AmericanBankingNews: CEO Stock Sale

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.